Rchr
J-GLOBAL ID:201901009474022326   Update date: Nov. 05, 2024

KAMBE ATSUSHI

KAMBE ATSUSHI
Affiliation and department:
Research theme for competitive and other funds  (3):
  • 2020 - 2023 初発膠芽腫のベバシズマブ治療効果に関与する遺伝子と画像評価法の確立
  • 2012 - 2015 The attempt of control of glioma dissemination lesions in Vandetanib
  • 2009 - 2011 The Investigation of tumor suppression effect of EP4 receptor inhibitors in glioblastoma
Papers (60):
  • Tomohiro Hosoya, Atsushi Kambe, Irfan Kesumayadi, Karen Makishima, Shuntaro Sueyoshi, Makoto Sakamoto, Masamichi Kurosaki. Mechanism and significance of diffusion restriction followed by calcification in high-grade glioma treated with bevacizumab. Scientific Reports. 2024. 14. 1
  • Irfan Kesumayadi, Makoto Sakamoto, Tomohiro Hosoya, Atsushi Kambe, Tetsuji Uno, Hiroki Yoshioka, Masamichi Kurosaki. Clinical Outcome of Pipeline Embolization Device with and without Coil to Treat Intracranial Aneurysm: A Systematic Review and Meta-Analysis. AJNR. American journal of neuroradiology. 2024
  • Atsushi Kambe, Shinichiro Kitao, Ryoya Ochiai, Tomohiro Hosoya, Shinya Fujii, Masamichi Kurosaki. The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment. Journal of neuro-oncology. 2024. 166. 1. 175-183
  • Tomohiro Hosoya, Atsushi Kambe, Daiou Miyamoto, Makoto Sakamoto, Masamichi Kurosaki. Papillary Glioneuronal Tumor Masquerading as Malignant Brain Tumors: A Case Report. Yonago acta medica. 2023. 66. 3. 385-388
  • 坂本 誠, 宇野 哲史, 中島 定男, 細谷 朋央, 桑本 雄平, 神部 敦司. 再発脳動脈瘤は血管内手術で制御可能か? FDを第一選択とした治療戦略. 脳血管内治療. 2022. 7. Suppl. S19-S19
more...
MISC (1):
Professional career (1):
  • 博士(医学) (鳥取大学)
Association Membership(s) (7):
THE JAPANESE SOCIETY FOR PEDIATRIC NEUROSURGERY ,  THE JAPAN STROKE SOCIETY ,  日本神経内視鏡学会 ,  日本脳腫瘍の外科学会 ,  日本脳腫瘍学会 ,  THE JAPAN SOCIETY OF BRAIN TUMOR PATHOLOGY ,  THE JAPAN NEUROSURGICAL SOCIETY
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page